Jeil·Hanlim’s authorized generics, challenge to the market

Circadin, original Melatonin, patent expired in June

Expect to expand ₩20 ~ 30 billion in 5 years

Boryeong, SKC, etc. will have Melatonin generics in November

Circadin‘s authorized generics are expected to be released to the market as early as next month.

 

According to the industry, Jeil, Hanlim, and CMG will release their products sequentially in March, April, and May through Kuhnil.

 

The reason for launching Circadin‘s authorized Generics seems to be aimed at the market for the patent expiration scheduled for this June.

 

Once the launch of authorized generics is completed in the first half, more than 10 pharmaceutical companies, including Boryeong, SK Chemicals, Yungjin, and Daewoong Bio, are expected to start pouring out in November.

 

Introduced in the domestic market in July 2014, Kuhnil’s Circadin is a sleep-inducing agent based on Melatonin.

 

Circadin was developed by Neuroim Phamaceuticals, a company specializing in the development of CNS-based senile diseases, and is currently marketed in 43 countries, including the UK, France and Italy..

 

Domestic copyright is monopolized by Kuhnil and forms ₩7~10 billion units in six years since its launch.

 

The market is expected to expand further if authorized generics and generics are added.

 

Circadin’s authorized generic drugs sold by Jeil, Hanlim, and CMG will be imported from Guhnil and supplied to these pharmaceutical companies.

 

Circadin, licensed as a prescription drug, currently costs ₩1,000 to ₩1200 per tablet.

 

The authurized generics seen by the industry are also expected to be formed at this price range.

 

The generic price is expected to be set at around ₩400 per party.

 

Circadin is the first drug to treat insomnia that restores brain and body function by controlling Melatonin.

 

Melatonin is a hormone secreted by the brain that can cause insomnia if it is not secreted or secreted less.

 

Circadin is the first sustained-release Melatonin released similarly to endogenous melatonin, which not only improves sleep quality but also has lower side effects than conventional drugs.

 

Indeed, domestic clinical trials of insomnia patients over the age of 55 have shown that the quality of sleep, time to sleep, total sleep time, sleep efficiency, and daytime activity after taking Circadin have improved, but no special side effects occur.

 

In addition, existing sleeping pills are limited to 3 to 4 weeks once for psychotropic drugs, whereas Circadin can be prescribed for up to 13 weeks once as a non-psychotropic drug.

 

Existing sleeping pills act on the GABA receptors that suppress the central nervous system, leading to adverse reactions such as daytime lethargy and addictiveness, but Circadin does not act on the GABA receptor and no such adverse event is observed.

 

Melatonin has been widely used as a food since the 1990s, as it has been proved to be effective and safe through long research.

 

However, Melatonin used in foods has a short half-life of 35 to 50 minutes and has a disadvantage in that it does not exhibit sufficient effect.

 

Circadin has been developed to exert its effects throughout sleep by increasing the half-life to about 4 hours with a sustained release technology to release a certain amount for 8-10 hours.